(ELIS) Elis - Ratings and Ratios
Linen, Workwear, Hygiene, Beverage, Disinfection
Dividends
| Dividend Yield | 1.94% |
| Yield on Cost 5y | 3.80% |
| Yield CAGR 5y | 7.80% |
| Payout Consistency | 72.3% |
| Payout Ratio | 30.4% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 25.4% |
| Value at Risk 5%th | 38.9% |
| Relative Tail Risk | -6.92% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.90 |
| Alpha | 20.23 |
| CAGR/Max DD | 0.84 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.540 |
| Beta | 0.110 |
| Beta Downside | -0.003 |
| Drawdowns 3y | |
|---|---|
| Max DD | 21.94% |
| Mean DD | 6.73% |
| Median DD | 4.94% |
Description: ELIS Elis November 05, 2025
Elis SA (ELIS) is a French-based provider of textile, hygiene and well-being services, operating across 15+ countries in Europe, the UK, Ireland, Latin America and other international markets. Its portfolio spans flat linens (table, bed, kitchen, patient, bath), workwear and personal protective equipment, beverage dispensers, floor protection, industrial wipes, pest-control and disinfection services, as well as washroom hygiene solutions and clean-room garments.
The company serves a diversified client base that includes catering, hospitality, healthcare and social-welfare institutions, industrial manufacturers, retail and service firms, plus public authorities. This breadth helps mitigate concentration risk, while the recurring-revenue model (service contracts and lease-back arrangements) provides stable cash flows.
Key recent metrics (FY 2023): revenue of €2.8 bn, EBITDA margin of ~8 %, and a net cash position of €300 m. Growth has been driven by a 5 % YoY increase in contract renewals, particularly in the healthcare and food-service segments, where regulatory pressure on hygiene standards is accelerating demand for reusable, ESG-compliant solutions. Labor cost inflation in Central and Eastern Europe remains a material headwind, prompting Elis to invest in automation and digital workflow platforms to protect margins.
Given the sector’s exposure to macro-economic trends such as inflation-linked cost pressures and the ongoing shift toward sustainable, reusable textiles, a deeper dive into Elis’s cost-structure initiatives and contract-renewal pipeline could be valuable; the ValueRay platform offers granular data and scenario analysis that may help clarify the company’s upside potential.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (614.0m TTM) > 0 and > 6% of Revenue (6% = 547.5m TTM) |
| FCFTA 0.12 (>2.0%) and ΔFCFTA 7.48pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -8.24% (prev -9.67%; Δ 1.43pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.30 (>3.0%) and CFO 2.75b > Net Income 614.0m (YES >=105%, WARN >=100%) |
| Net Debt (3.83b) to EBITDA (3.10b) ratio: 1.24 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.66 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (258.9m) change vs 12m ago -1.70% (target <= -2.0% for YES) |
| Gross Margin 42.57% (prev 42.30%; Δ 0.27pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 100.6% (prev 76.65%; Δ 23.91pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 4.08 (EBITDA TTM 3.10b / Interest Expense TTM 291.6m) >= 6 (WARN >= 3) |
Altman Z'' 1.03
| (A) -0.08 = (Total Current Assets 1.49b - Total Current Liabilities 2.24b) / Total Assets 9.17b |
| (B) 0.15 = Retained Earnings (Balance) 1.33b / Total Assets 9.17b |
| (C) 0.13 = EBIT TTM 1.19b / Avg Total Assets 9.07b |
| (D) 0.20 = Book Value of Equity 1.14b / Total Liabilities 5.60b |
| Total Rating: 1.03 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 78.42
| 1. Piotroski 6.50pt |
| 2. FCF Yield 11.08% |
| 3. FCF Margin 11.57% |
| 4. Debt/Equity 1.14 |
| 5. Debt/Ebitda 1.24 |
| 6. ROIC - WACC (= 7.55)% |
| 7. RoE 17.45% |
| 8. Rev. Trend 63.36% |
| 9. EPS Trend 1.61% |
What is the price of ELIS shares?
Over the past week, the price has changed by -2.94%, over one month by -5.86%, over three months by -3.82% and over the past year by +24.17%.
Is ELIS a buy, sell or hold?
What are the forecasts/targets for the ELIS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 27.8 | 19.9% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 27.6 | 19.2% |
ELIS Fundamental Data Overview December 12, 2025
Market Cap EUR = 5.51b (5.51b EUR * 1.0 EUR.EUR)
P/E Trailing = 15.9865
P/E Forward = 11.0011
P/S = 1.1791
P/B = 1.5102
Beta = 1.241
Revenue TTM = 9.12b EUR
EBIT TTM = 1.19b EUR
EBITDA TTM = 3.10b EUR
Long Term Debt = 2.34b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.23b EUR (from shortTermDebt, last quarter)
Debt = 4.06b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.83b EUR (from netDebt column, last quarter)
Enterprise Value = 9.53b EUR (5.51b + Debt 4.06b - CCE 39.3m)
Interest Coverage Ratio = 4.08 (Ebit TTM 1.19b / Interest Expense TTM 291.6m)
FCF Yield = 11.08% (FCF TTM 1.06b / Enterprise Value 9.53b)
FCF Margin = 11.57% (FCF TTM 1.06b / Revenue TTM 9.12b)
Net Margin = 6.73% (Net Income TTM 614.0m / Revenue TTM 9.12b)
Gross Margin = 42.57% ((Revenue TTM 9.12b - Cost of Revenue TTM 5.24b) / Revenue TTM)
Gross Margin QoQ = 45.74% (prev 46.24%)
Tobins Q-Ratio = 1.04 (Enterprise Value 9.53b / Total Assets 9.17b)
Interest Expense / Debt = 1.82% (Interest Expense 74.0m / Debt 4.06b)
Taxrate = 29.27% (63.1m / 215.6m)
NOPAT = 840.7m (EBIT 1.19b * (1 - 29.27%))
Current Ratio = 0.66 (Total Current Assets 1.49b / Total Current Liabilities 2.24b)
Debt / Equity = 1.14 (Debt 4.06b / totalStockholderEquity, last quarter 3.58b)
Debt / EBITDA = 1.24 (Net Debt 3.83b / EBITDA 3.10b)
Debt / FCF = 3.62 (Net Debt 3.83b / FCF TTM 1.06b)
Total Stockholder Equity = 3.52b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.69% (Net Income 614.0m / Total Assets 9.17b)
RoE = 17.45% (Net Income TTM 614.0m / Total Stockholder Equity 3.52b)
RoCE = 20.28% (EBIT 1.19b / Capital Employed (Equity 3.52b + L.T.Debt 2.34b))
RoIC = 11.79% (NOPAT 840.7m / Invested Capital 7.13b)
WACC = 4.24% (E(5.51b)/V(9.57b) * Re(6.42%) + D(4.06b)/V(9.57b) * Rd(1.82%) * (1-Tc(0.29)))
Discount Rate = 6.42% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -4.47%
[DCF Debug] Terminal Value 81.43% ; FCFE base≈777.9m ; Y1≈959.7m ; Y5≈1.64b
Fair Price DCF = 119.7 (DCF Value 27.85b / Shares Outstanding 232.6m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 1.61 | EPS CAGR: -37.33% | SUE: 0.0 | # QB: 0
Revenue Correlation: 63.36 | Revenue CAGR: 18.93% | SUE: N/A | # QB: 0
EPS next Year (2026-12-31): EPS=1.99 | Chg30d=-0.000 | Revisions Net=+0 | Growth EPS=+7.0% | Growth Revenue=+4.2%